Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(6):415-416; doi:10.1093/jnci/94.6.415
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Dunn, F. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dunn, F. B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 6, 415-416, March 20, 2002
© 2002 Oxford University Press

NEWS

Value of Prostate-Specific Antigen: Are Higher Levels Meaningful?

F. B. Dunn

In 1987, Stanford University’s Thomas Stamey, M.D., published a seminal study in the New England Journal of Medicine that concluded that, as prostate tumors worsened, prostate-specific antigen levels rose in sync. Based on this and supporting reports, PSA testing gained fame, exploding to several million tests per year by the mid-1990s.


Figure Removed (Available Only in the Full Text)
View larger version (126K):
[in this window]
[in a new window]
  		Dr. Thomas Stamey

 
But, like a rueful parent reflecting on childhood transgressions, Stamey wishes he knew then what he knows now. In January of this year, he published what again may turn out to be an influential report. This paper, carried in the Journal of Urology, concludes that PSA is "clinically useless" in staging prostate cancer or . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?